- Conditions
- Leukemia, Lymphoma, Tumor Lysis Syndrome, Hyperuricemia
- Interventions
- Rasburicase
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 11
- States / cities
- Palo Alto, California • San Diego, California • Indianapolis, Indiana + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2593–2616
of 22,555
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Interventions
- NEOK002, NEOK002 RDE
- Drug
- Lead sponsor
- NEOK Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 10
- States / cities
- Orlando, Florida • New York, New York • Nashville, Tennessee + 5 more
- Conditions
- Parkinson Disease, Depression
- Interventions
- paroxetine, venlafaxine, placebo
- Drug · Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 15
- States / cities
- San Francisco, California • Gainesville, Florida • Miami, Florida + 11 more
- Conditions
- Atopic Dermatitis
- Interventions
- DMT210 Topical Gel, Vehicle Control
- Drug
- Lead sponsor
- Dermata Therapeutics
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Houston, Texas • Norfolk, Virginia
- Conditions
- Acute Ischaemic Stroke, Transient Ischaemic Attack
- Interventions
- ticagrelor, Acetylsalicylic acid (ASA)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 130 Years
- Enrollment
- 13,307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 115
- States / cities
- Montgomery, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 112 more
- Conditions
- Stress Disorders, Post-Traumatic, Sleep Disorders
- Interventions
- MEDVAMC Nightmare Treatment, Telepsychiatry Nightmare Treatment
- Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Radiographic Contrast Agent Nephropathy
- Interventions
- CINCOR™ System and contrast conservation unit (CCS-1), Standard of Care plus peri-procedural hydration
- Device · Other
- Lead sponsor
- Osprey Medical, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 20
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- albiglutide, insulin glargine
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 779 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 314
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 252 more
- Conditions
- Nurse's Role, Nurse-Patient Relations, Satisfaction, Patient Fall
- Interventions
- Rehab MATRIX
- Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glioblastoma Multiforme
- Interventions
- ICT-107, Placebo DC
- Biological
- Lead sponsor
- Precision Life Sciences Group
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 25
- States / cities
- South Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 17 more
- Conditions
- Shoulder and Upper Arm Injury
- Interventions
- Not listed
- Lead sponsor
- Texas Woman's University
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Crohn Disease
- Interventions
- Ozanimod
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 854 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 190
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 142 more
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
- Interventions
- Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Waiting List
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- BMS-986393, Alnuctamab, Mezigdomide, Iberdomide, Elranatamab, Dexamethasone
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 11 more
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Elobixibat 10 mg
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 53
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • North Little Rock, Arkansas + 46 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy, Behavior Therapy
- Drug · Behavioral
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Fatigue
- Interventions
- Methylphenidate, Fatigue Evaluations
- Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor
- Interventions
- NTX-1088, Pembrolizumab
- Drug
- Lead sponsor
- Nectin Therapeutics Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Duarte, California • New Orleans, Louisiana • Houston, Texas
- Conditions
- Aortic Arch Aneurysm, Aortic Arch Dissection, Chronic Aortic Dissection, Acute Aortic Dissection
- Interventions
- Arcevo™ LSA Hybrid Stent Graft System
- Device
- Lead sponsor
- Artivion Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 16 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Placebo, PF-06700841 15 mg, PF-06700841 30 mg, PF-06700841 45 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Fullerton, California • La Palma, California + 34 more
- Conditions
- Congenital Heart Disease, Hypoplastic Left Heart Syndrome, Transposition of the Great Arteries, Aortic Arch Hypoplasia or Interruption
- Interventions
- Erythropoetin, Normal saline
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Day to 30 Days
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
- Interventions
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Fludarabine Phosphate, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Vorinostat
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatitis C, Genotype 1
- Interventions
- Daclatasvir, Ribavirin, PEG-Interferon alfa 2a
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 104
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Mobile, Alabama + 84 more